COVID-19NCT05087199
COVID-19 Infection in Patients With Chronic Pulmonary Diseases.
An observational study of COVID-19 and Chronic Pulmonary Disease, run by Sohag University.
Trial summary
This study aims to assess the clinical presentation, radiological patterns and outcome of COVID-19 infection in patients with chronic pulmonary disease. Inter-relationship between the severity of COVID-19 infection and chronic pulmonary diseases. Read more about this study
- Who is it for?
- Ages 16 to 100 years
- Conditions the study is for
- COVID-19, Chronic Pulmonary Disease
- What is being tested?
- Rt-PCR.
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 Nov 2021to 30 Jul 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 100 years
- All sexes
- Child, Adult, Older adult
Study population: Community sample with chronic pulmonary diseases
Who may be able to join
- Subjects with confirmed diagnosis of COVID-19 infection by:
- RT-PCR And Chest Computed tomography and laboratoty investigations. Patients with chronic chest disease including (COPD, bronchial asthma, ILD, bronchiectasis).
Who cannot join
- Those who are diagnosed with viral pneumonia caused by viruses other than COVID-19.
- Those who are not confirmed to be COVID-19 with PCR or by radiological and laboratory investigations.
About this study
This study aims to assess the clinical presentation, radiological patterns and outcome of COVID-19 infection in patients with chronic pulmonary disease.
Inter-relationship between the severity of COVID-19 infection and chronic pulmonary diseases.
Read the detailed description
The COVID-19 pandemic has led to many difficulties with the diagnosis and routine management of chronic pulmonary diseases such as COPD, Bronchial asthma, ILD and Bronchiectasis as well as raising concerns about the management and outcomes for patients with these diseases who develop COVID-19.
Although there is conflicting evidence on whether patients with chronic respiratory diseases are more susceptible to COVID-19, these patients exhibit a more severe presentation and higher mortality compared with those without chronic respiratory diseases.
- Conditions
- COVID-19, Chronic Pulmonary Disease
- Being tested
- Rt-PCR.
- Keywords
- COVID-19, Chronic pulmonary disease
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rt-PCR.Diagnostic test
Also called Ct chest, D-dimer, CRP
Nasopharyngeal swab for Rt-PCR for COVID-19
What is being measured
The primary outcome is the main question the study is designed to answer.
Effect of COVID-19 on patients with chronic pulmonary diseases
Measured: 2 weeks after patient confirmation of infection by COVID-19
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2021
- Study start1 Nov 2021 (estimated)
- Primary completion30 Jun 2022 (estimated)
- Study completion30 Jul 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mostafa Mahmoud Elsayed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05087199
- Sponsor's protocol ID
- OHRP#:IRB00013006
- Status last verified
- Oct 2021
- First submitted
- 20 Oct 2021
- Last updated
- 2 Nov 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- COVID-19 Infection in Patients With Chronic Pulmonary Diseases.
- ClinicalTrials.gov ID
- NCT05087199
- Acronym / sponsor ID
- OHRP#:IRB00013006
- Conditions
- COVID-19, Chronic Pulmonary Disease
- Keywords
- COVID-19, Chronic pulmonary disease
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Nov 2021 (estimated)
- Primary completion
- 30 Jun 2022 (estimated)
- Study completion
- 30 Jul 2022 (estimated)
- First posted
- 21 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to assess the clinical presentation, radiological patterns and outcome of COVID-19 infection in patients with chronic pulmonary disease.
Inter-relationship between the severity of COVID-19 infection and chronic pulmonary diseases.
Detailed description
The COVID-19 pandemic has led to many difficulties with the diagnosis and routine management of chronic pulmonary diseases such as COPD, Bronchial asthma, ILD and Bronchiectasis as well as raising concerns about the management and outcomes for patients with these diseases who develop COVID-19.
Although there is conflicting evidence on whether patients with chronic respiratory diseases are more susceptible to COVID-19, these patients exhibit a more severe presentation and higher mortality compared with those without chronic respiratory diseases.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 16 to 100 years
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Community sample with chronic pulmonary diseases
Key inclusion criteria (2 listed)
- Subjects with confirmed diagnosis of COVID-19 infection by:
- RT-PCR And Chest Computed tomography and laboratoty investigations. Patients with chronic chest disease including (COPD, bronchial asthma, ILD, bronchiectasis).
Key exclusion criteria (2 listed)
- Those who are diagnosed with viral pneumonia caused by viruses other than COVID-19.
- Those who are not confirmed to be COVID-19 with PCR or by radiological and laboratory investigations.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rt-PCR.Also: Ct chest, D-dimer, CRPNasopharyngeal swab for Rt-PCR for COVID-19 | Diagnostic test | – |
Primary outcome
Effect of COVID-19 on patients with chronic pulmonary diseases
Time frame: 2 weeks after patient confirmation of infection by COVID-19
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2021.
Related trials for COVID-19
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
RecruitingPhase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Coronavirus Disease (COVID-19)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 and Chronic Pulmonary Disease, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effect of COVID-19 on patients with chronic pulmonary diseases (time frame: 2 weeks after patient confirmation of infection by COVID-19). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2021; AzTrials last refreshed its copy on 7 Nov 2026.